We participate in numerous events promoting our portfolio companies and meeting our clients.

News

RhoVac, a Ventac Partners portfolio company, announced that all patients in the company’s clinical phase I/II study successfully completed their treatment phase with RV001. For more information, please visit this link.

RhoVac, Ventac Partners portfolio company, reports positive pre-submission meeting with the European Medicines Agency. For more information, please visit this link.

Subscribe to our Newsletter

Thank you!